Skip to content

Abiomed coverage assumed by Piper at buy, target $145

April 6, 2017

Piper Jaffray assumes coverage on ABIOMED (NASDAQ: ABMD) with a Overweight rating and a price target of $145.00.

Analyst Matt O’Brien believes a premium valuation is warranted in light of strong revenue growth outlook, lacking competition, and strength of potential earnings power.

His FY 2017 EPS estimate is $1.18, FY 2018 EPS estimate is $1.81.

http://bit.ly/2oIIDIl

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: